title: Biweekly intracavernous administration of papaverine for erectile dysfunction.
abstract: To determine the efficacy of the intracavernous administration of papaverine hydrochloride every 2 weeks to treat male impotence, we recruited 50 patients from a sexual dysfunction clinic. Of these, 8 did not complete the course of papaverine therapy. A total of 8 had complications, including priapism in 3 and ecchymoses or urethral bleeding in 5. In 30 patients who had substantial vasculogenic disease, there was a notable improvement in the penile blood pressure after papaverine treatment, although only 9 reported successful sexual intercourse. The penile blood pressure in the remaining 12 patients without substantial vascular disease increased modestly after therapy, and 5 persons reported satisfactory sexual activity. We conclude that administering papaverine intracavernosally every 2 weeks improves sexual potency in a subset of sexually impotent patients. Those with severe vasculogenic disease and a penile-brachial pressure index of less than 0.65 are not good candidates for this regimen.
authors.forename: A D
authors.initials: AD
authors.lastname: Mooradian
authors.forename: J E
authors.initials: JE
authors.lastname: Morley
authors.forename: F E
authors.initials: FE
authors.lastname: Kaiser
authors.forename: S S
authors.initials: SS
authors.lastname: Davis
authors.forename: S P
authors.initials: SP
authors.lastname: Viosca
authors.forename: S C
authors.initials: SC
authors.lastname: Korenman
mesh_terms: D000328:Adult; D000368:Aged; D007172:Erectile Dysfunction / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010410:Penile Erection / Q000187:drug effects*
chemical_list: D010208:Papaverine